These studies indicate that ketoconazole or erythromycin co-administration enhances fexofenadine gastrointestinal absorption. It is freely soluble in methanol and ethanol, slightly soluble in chloroform and water, and insoluble in hexane.
The aqueous tablet film coating is made from hypromellose, iron oxide blends, polyethylene glycol, povidone, silicone dioxide, and titanium dioxide. In laboratory animals, no anticholinergic or alpha1-adrenergic blocking effects were observed. ALLEGRA is formulated as a tablet for oral
Allegra D XR Each tablet contains 30, 60, or 180 mg fexofenadine hydrochloride (depending on the dosage strength) and the following excipients: croscarmellose sodium, magnesium stearate, microcrystalline cellulose, and pregelatinized starch. Moreover, no sedative or other central nervous system effects were observed. The administration of 30 mg ALLEGRA Oral Suspension with a high fat meal decreased the AUC and the mean Cmax by approximately 30 and 47%, respectively in healthy adult subjects. Efficacy was demonstrated by a significant reduction in mean pruritus scores (MPS), mean number of wheals (MNW), and mean total symptom scores (MTSS, the sum of the MPS and MNW score). Fexofenadine hydrochloride, the major active metabolite of terfenadine, is an antihistamine with selective peripheral H1-receptor antagonist activity. After administration of a single 60 mg capsule to healthy subjects, the mean maximum plasma concentration (Cmax) was 131 ng/mL. A dose of 5 mL of ALLEGRA Oral Suspension containing 30 mg of fexofenadine hydrochloride is bioequivalent to a 30 mg dose of ALLEGRA tablets. Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.
Similar reductions were observed for mean number of wheals and mean pruritus score at the
Allegra D Line of the 24-hour dosing interval.
Allegra D Coupons the absolute bioavailability
Allegra D Line fexofenadine hydrochloride has not been established, it is unknown if the fecal component represents primarily unabsorbed drug or the result of biliary excretion.
The mean elimination half-life of fexofenadine was 14.4 hours following administration of 60 mg twice daily in healthy subjects. This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.